WallStreetZenWallStreetZen

NASDAQ: IMUX
Immunic Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for IMUX

Based on 1 analyst offering 12 month price targets for Immunic Inc.
Min Forecast
$10.00+693.65%
Avg Forecast
$10.00+693.65%
Max Forecast
$10.00+693.65%

Should I buy or sell IMUX stock?

Based on 1 analyst offering ratings for Immunic Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their IMUX stock forecasts and price targets.

IMUX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-05

1 of 1

Forecast return on equity

Is IMUX forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.16%

Forecast return on assets

Is IMUX forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

IMUX revenue forecast

What is IMUX's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$699.9M
Avg 2 year Forecast
$528.6M
Avg 3 year Forecast
$580.3M

IMUX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IMUX$1.26$10.00+693.65%Strong Buy
SEER$1.75N/AN/A
RNAC$20.90$47.00+124.88%Buy
VXRT$0.66$2.00+203.95%Strong Buy
MCRB$0.74$4.75+539.30%Hold
View Top Biotech Stocks

Immunic Stock Forecast FAQ

Is Immunic Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: IMUX) stock is to Strong Buy IMUX stock.

Out of 1 analyst, 1 (100%) are recommending IMUX as a Strong Buy, 0 (0%) are recommending IMUX as a Buy, 0 (0%) are recommending IMUX as a Hold, 0 (0%) are recommending IMUX as a Sell, and 0 (0%) are recommending IMUX as a Strong Sell.

If you're new to stock investing, here's how to buy Immunic stock.

What is IMUX's revenue growth forecast for 2026-2028?

(NASDAQ: IMUX) Immunic's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Immunic's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast IMUX's revenue for 2026 to be $62,944,016,169, with the lowest IMUX revenue forecast at $62,944,016,169, and the highest IMUX revenue forecast at $62,944,016,169. On average, 2 Wall Street analysts forecast IMUX's revenue for 2027 to be $47,535,578,567, with the lowest IMUX revenue forecast at $269,787,048, and the highest IMUX revenue forecast at $94,801,370,087.

In 2028, IMUX is forecast to generate $52,184,908,695 in revenue, with the lowest revenue forecast at $4,073,784,425 and the highest revenue forecast at $127,787,333,156.

What is IMUX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: IMUX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is IMUX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year IMUX price target, the average IMUX price target is $10.00, with the highest IMUX stock price forecast at $10.00 and the lowest IMUX stock price forecast at $10.00.

The Wall Street analyst predicted that Immunic's share price could reach $10.00 by Apr 5, 2025. The average Immunic stock price prediction forecasts a potential upside of 693.65% from the current IMUX share price of $1.26.

What is IMUX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: IMUX) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.